Our resource hub to discover reports, policy papers and other forms of informative content
Innovative Medicines Canada has submitted formal feedback to the Patented Medicine Prices Review Board’s (PMPRB) revised Draft Guidelines public consultation, calling for a suspension of the planned implementation to ensure meaningful stakeholder consultation and a thorough impact analysis.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
*Cette lettre est disponible en anglais seulement.
IMC calls for a suspension of the Patented Medicine Prices Review Board’s (PMPRB) guidelines consultation process.
IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.
This submission responds to PMPRB’s consultation on its proposed Guideline Monitoring and Evaluation Plan GMEP, deeming it premature.
IMC requests that the Honourable Patty Hadju suspend the July 1, 2021 implementation of regulatory changes to the PMPRB until the COVID-19 pandemic has abated.
The industry calls on the federal government to delay implementation of PMPRB regulatory changes until the COVID-19 pandemic has abated. IMC urges the federal government to work with our industry to build a more vibrant life sciences sector – one that enhances patients’ access to innovative medicines and tackles the sector’s critical issues.
IMC opposes a January 15, 2021 proposal to redefine ‘gap’ medicines and change the timeline for compliance – which halves the transition period to six months.
The industry campaigns to remove experimental “new economic factors” from regulations – the source of most stakeholder concerns amid 2020 PMPRB changes. IMC encourages government to delay implementation of changes until the COVID-19 pandemic has abated.
Informative content to keep you up to date on the most pressing issues facing our industry.
